Ranked internationally and domestically, our pharmaceutical, biopharmaceutical and life sciences focussed lawyers and attorneys are recognised as being among the best IP practitioners in the world.
Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys, to the pharmaceutical, biopharmaceutical and life sciences industries.
We coordinate and execute local and multi-jurisdictional IP litigation strategies, provide IP/legal support for regional and global business development activities and licensing deals, and prosecute patent and trade mark applications around the world.
IP SPECIALISTS LAWYERS – PATENT ATTORNEYS – TRADE MARK ATTORNEYS
PEARCE IP BLOG
Read our latest updates & insights
BioBlast® w/e 27 Jan 23: Alvotech Simlandi® (biosimilar adalimumab) approval, Alvotech completes private placement round, PTAB institutes Mylan aflibercept challenges, Dr Reddy’s rituximab, BeiGene’s denosumab, MHRA grants Ximluci® (biosimilar ranibizumab) marketing authorisation, NMPA approves BAT1806 (biosimilar tocilizumab), Genentech and Tanvex settlement, Luye Pharma denosumab
Significant biosimilar activities this week include: 24 Jan 23 | Saudi Food & Drug Authority approves Alvotech’s...
BioBlast® w/e 13 Jan 23: Alvotech’s golimumab, Alvotech and Fuji commercialisation partnership, Dong-A ST’s ustekinumab, Coherus and Klinge’s deal for US aflibercept, Boan Biotech and CP Qingdao denosumab deal, Rani and Celltrion’s oral ustekinumab biosimilar
Significant biosimilar activities this week include: 16 Jan 23 | Dong-A ST publishes the results of Ph III trials of...
Product specific reports based on extracts from our BioBlast® database
By 2027, be the premier life sciences IP practice in Australia.
AWARD WINNING IP SPECIALISTS LAWYERS - PATENT ATTORNEYS - TRADE MARK ATTORNEYS